Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience

MLA

Chisako Fujiwara, et al. “Real‐world Effectiveness and Safety of Dupilumab in Patients with Moderate and Severe Atopic Dermatitis: 2‐year Experience.” Journal of Cutaneous Immunology and Allergy, vol. 6, no. 3, June 2023, pp. 88–93. EBSCOhost, https://doi.org/10.1002/cia2.12280.

APA

Chisako Fujiwara, Akihiko Uchiyama, Yuta Inoue, Mai Ishikawa, & Sei‐ichiro Motegi. (2023). Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience. Journal of Cutaneous Immunology and Allergy, 6(3), 88–93. https://doi.org/10.1002/cia2.12280

Chicago

Chisako Fujiwara, Akihiko Uchiyama, Yuta Inoue, Mai Ishikawa, and Sei‐ichiro Motegi. 2023. “Real‐world Effectiveness and Safety of Dupilumab in Patients with Moderate and Severe Atopic Dermatitis: 2‐year Experience.” Journal of Cutaneous Immunology and Allergy 6 (3): 88–93. doi:10.1002/cia2.12280.